Best Life Sciences Companies in Provence Alpes Cote d Azur, France
The 67 best Life Sciences companies in Provence Alpes Cote d Azur, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Nicox.
Our analysis of 50 Life Sciences companies
$3.3b in tracked funding; 62% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Provence Alpes Cote d Azur
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Nicox Developer of nitric oxide (NO) based therapeutics for glaucoma | $271M | 43 mo ago | 28 | Michele Garufi Co-Founder and Board Member | WordPressMySQLPHP+16 | Top 10M | 971 patents Ocular nitric‑oxide‑releasing therapeutics for treating eye vascular and neuro‑degenerative disorders | 1 partnership |
| 2 | Imcheck Therapeutics Developer of immunotherapeutic antibodies for the treatment of multiple diseases 55Patents top 21%Funding top 24%Moat top 26%Innovation top 27% All 9 signals ▾Patentstop 21% Fundingtop 24% Moattop 26% Innovationtop 27% Markettop 49% Talentbottom 49% Globalbottom 45% Techbottom 30% Newsbottom 27% Patents: 104 patents matched (strict assignee match) · 75 filings since 2022 vs 29 in 2017-21 Funding: Raised $185M across 6 rounds · 6 rounds over 9 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $185M | 21 mo ago | 48 | Pierre D'epenoux Chief Executive Officer | — | — | 104 patents BTN3A-targeted immunotherapies for cancer/infections and novel antibacterial treatments | — |
| 3 | SuperSonic Imagine Developer of ultrasound platforms for imaging | $130M | 115 mo ago | 113 | Jacques Souquet Founder & CEO | SentryTypeScriptGraphQL+15 | Top 10M | 350 patents Advanced ultrasonic imaging and signal processing for medical diagnostic devices | — |
| 4 | Txcell Developer of personalized immunotherapies for chronic inflammatory diseases | $45M | 112 mo ago | 45 | Sandy Macrae CEO | — | — | 186 patents Cellular immunotherapy using regulatory T cells and anti‑HLA antibodies for autoimmune/B‑cell diseases | — |
| 5 | Innate Pharma Developer of antibody based therapeutics to treat cancer 76Fin. health top 17%Patents top 21%Funding top 28%Talent top 28% All 11 signals ▾Fin. healthtop 17% Patentstop 21% Fundingtop 28% Talenttop 28% Innovationtop 32% Markettop 34% Moattop 40% Globaltop 48% Techbottom 49% Growthbottom 47% Newsbottom 47% Fin. health: Revenue ~$62.3M (FY2016) · Net margin 23.3% Patents: 1,175 patents matched (strict assignee match) · 266 filings since 2022 vs 455 in 2017-21 rank vs industry peers · Fliar Intelligence Index 76/100 | $43M | 14 mo ago | 191 | Marc Bonneville Co-Founder | Apple iCloud MailMicrosoft 365Q4+14 | Top 5M | 1,170 patents Engineered immune cell therapies and antibody engineering for cancer immunotherapy | — |
| 6 | DiogenX Developer of therapeutics for the treatment of diabetes | $35M | 32 mo ago | 9 | Patrick Collombat Co-Founder | — | — | 17 patents Engineered recombinant R‑spondin proteins for therapeutic tissue regeneration | — |
| 7 | Adcytherix Developer of therapeutics for the treatment of cancer 40Growth top 15%News top 22%Funding top 31%Moat top 42% All 8 signals ▾Growthtop 15% Newstop 22% Fundingtop 31% Moattop 42% Talentbottom 49% Globalbottom 39% Marketbottom 28% Techbottom 20% Growth: Fresh capital in last 24 mo News: 6 BI events in 12 mo (of 8 tracked, 3 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $32M | 8 mo ago | — | Carsten Dehning Co-Founder | WordPressMySQLPHP+12 | Top 50M | — | 1 award |
| 8 | HalioDx Developer of diagnostic product for colon cancer | $31M | 89 mo ago | 240 | — | — | — | — | — |
| 9 | InnoSkel Developer of novel therapeutic solutions for the treatment of skeletal disorders | $24M | 66 mo ago | 27 | Elvire Gouze Founder & CEO | — | — | 6 patents Gene‑based therapies targeting collagen synthesis and bone fragility disorders | — |
| 10 | Vect-Horus Peptide-vector drug development company focussing on blood-brain barrier technology for CNS and cancer… | $23M | 52 mo ago | 36 | Michel Khrestchatsky Co-Founder | SPIPPleskPHP+10 | Top 50M | 86 patents Receptor-targeted drug delivery and imaging agents for CNS, muscle, lung, and cancer therapies | 1 partnership |
| 11 | Trophos Research based pharma company focused on developing treatment for spinal muscular atrophy | $16M | 206 mo ago | 17 | — | — | — | 207 patents Cholesterol oxime derivatives and liposomal formulations for pharmaceutical drug delivery | — |
| 12 | Graftys Developer of bone graft substitutes and biocompatible filling materials | $12M | 47 mo ago | 25 | — | — | — | 75 patents Injectable calcium‑phosphate bone and dental cements with blood or hyaluronic acid additives | — |
| 13 | PhysioAssist Online marketplace connecting bike buyers with retailers | $7M | 105 mo ago | 16 | Adrien Mithalal Founder & CEO | WordPressMySQLPHP+22 | Top 50M | — | — |
| 14 | Median Provider of medical imaging software and services for clinical trials usage | $5M | 62 mo ago | 163 | Fredrik Brag Founder & CEO | WordPress Site EditorWordPressApple iCloud Mail+20 | Top 10M | 2 patents Automated quantitative texture analysis and lesion classification in chest CT imaging. | 1 partnership |
| 15 | Feeligreen Trans-dermal micro-current based drug delivery devices for dermatology | $5M | 108 mo ago | 9 | — | WordPressMySQLPHP+17 | Top 5M | 111 patents Dermatological and cosmetic skin treatment devices for therapeutic and aesthetic applications. | — |
| 16 | Biocyte Manufacturer of health supplements and personal care products | $4M | 91 mo ago | 50 | Philippe Bruneau Founder & CEO | Cart FunctionalityShopifyEasyGift+25 | Top 1M | 4 patents High‑melanin olive extracts for skin‑care and cosmetic formulations | — |
| 17 | AmiKana.BioLogics Developing yeast cell-based tools to evaluate drug resistance primarily for viral infections | $3M | 136 mo ago | — | Pablo Gluschankof Co-Founder & CEO | — | — | 4 patents Patents concentrated in chemistry & materials | — |
| 18 | C4Diagnostics Provider of technology for detection and count of microorganisms | $2M | 88 mo ago | 31 | Sam Dukan Co-Founder & Co-CEO | — | — | 4 patents Rapid antimicrobial susceptibility testing and nucleic‑acid based microbial detection. | — |
| 19 | Bilhi Genetics Disease prediction algorithms using genetic markers | $1M | 124 mo ago | 11 | Bruno Dessein Co-Founder | — | — | — | — |
| 20 | OZ BIOSCIENCES Developer of molecular delivery systems for transfection and transduction | $1M | 77 mo ago | 18 | Olivier Zelphati CEO & President | PrestaShopCart FunctionalityMySQL+12 | Top 10M | 11 patents Cationic poloxamer and lipid vectors for intracellular delivery of nucleic acids | 2 launchs |
| 21 | Hiphen Provider of agricultural imaging solutions and plant phenotyping data platform | $491K | 37 mo ago | 28 | — | WordPressTypeScriptPHP+33 | Top 50M | — | — |
| 22 | Tinteo Developer of audio listening devices | $265K | 168 mo ago | 5 | — | WordPressMySQLPHP+9 | Top 10M | — | — |
| 23 | AmyPore Developer of chimeric peptide for neurodegenerative diseases | $111K | 78 mo ago | 24 | — | — | — | — | — |
Top 12 Life Sciences companies in Provence Alpes Cote d Azur
#1
Series A · Marseille, Provence Alpes Cote d Azur · founded 2023$32.3Mraised▾
Developer of therapeutics for the treatment of cancer. It offers antibody drug conjugates to treat pathologies in high medical need, notably cancer.
- Oct 2025Series A$122M
- Jun 2024Seed$32.3M
#2
Public · Marseille, Provence Alpes Cote d Azur · founded 1999 · 191 employees$43.5Mraised▾
Developer of antibody-based therapeutics to treat cancer. The company's portfolio include lacutamab, developed in an advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab in non-small cell lung cancer, as well as ANKET multi-specific NK cell engagers to address multiple tumor types.
- Apr 2025Post IPO$17.1M
- Jun 2018Grant (prize money)$306.7K
- Jan 2017Post IPO$15M
- Jun 2014Post IPO$68.1M
#3
Acquired · Marseille, Provence Alpes Cote d Azur · founded 2015 · 48 employees$185.1Mraised▾
Developer of immunotherapeutic antibodies for the treatment of multiple diseases. It offers a new generation of proprietary immunomodulatory antibodies acting on both adaptive and innate immunity (notably gamma-delta T-cells). It offers therapeutics for cancer, infectious disease, and autoimmune disease.
- Aug 2024Grant (prize money)$22.4M
- Jun 2022Series C$103M
- Sep 2020Series B$7.1M
- Dec 2019Series B$53.2M
#4
Public · Valbonne, Provence Alpes Cote d Azur · founded 1996 · 28 employees$271Mraised▾
Developer of nitric oxide (NO) based therapeutics for glaucoma. The company has developed Nitric Oxide (NO) donating compounds that are used to maintain the intraocular pressure (IOP) in the eyes to prevent glaucoma. The company's lead candidates are VYZULTA (licensed), NCX 470 (phase III), and PDE5 inhibitors (research) to treat glaucoma, NCX 4251 (phase II) to treat blepharitis/dry eyes, ZERVIATE (licensed) to treat allergic conjunctivitis, and NCX 4280 to treat morning eye congestion.
- Nov 2022Series C$10.3M
- Dec 2021Series C$17M
- Dec 2020Series C$18.2M
- Nov 2019Series C$13.8M
#5
Series A · Marseille, Provence Alpes Cote d Azur · founded 2019 · 9 employees$35.2Mraised▾
Diogen Therapeutics has developed biologics to manage diabetes. The company has developed a novel recombinant protein to regenerate functional pancreatic islets to prevent pancreatic beta-cell degradation and rebalance glucose/insulin homeostasis.
- Oct 2023Grant (prize money)$2.6M
- May 2023Series A$33.8M
- Mar 2023Grant (prize money)$10.2M
- Jun 2020Seed$5.1M
#6
Public · Aix en provence, Provence Alpes Cote d Azur · founded 2005 · 113 employees$129.8Mraised▾
Supersonic Imagine is a developer of ultrasound platforms for imaging. It develops ultrasound platforms and its flagship product Aixplorer is composed of UltraFast Imaging to enable faster image capture, ShearWave Elastography for quantitative local stiffness, UltraFast Doppler for faster blood flow analysis and SonicSoftware. The applications include women's healthcare, vascular, hepatology or gastroenterology, and general imaging.
- Nov 2016Grant (prize money)$47.1K
- Apr 2013PE$35.9M
- Nov 2010Series C$45.7M
- May 2009Series B$36.3M
#7
Series D · Marseille, Provence Alpes Cote d Azur · founded 2005 · 36 employees$23.2Mraised▾
Vect-Horus is a French biotechnology company focused on developing drugs for the treatment of brain and central nervous system disorders.They work on small peptide vectors (8 - 10 amino acid long) for drugs (such as antibodies) to cross the blood-brain barrier. In 2015, they signed partnerships with 2 pharmaceutical companies, Sanofi and Servier Laboratories of undisclosed values. Apart from the partnerships, they have 8 own molecules in development. Their 1st drug, VH-N439, entered regulatory preclinical stages (as on Mar 2015).
- Feb 2022Grant (prize money)$1M
- Dec 2020Series D$6.5M
- Sep 2020Series D$7.9M
- Jun 2018Series B$4.1M
#8
Series C · Aix en provence, Provence Alpes Cote d Azur · founded 2005 · 25 employees$12Mraised▾
Graftys develops bone graft substitutes, osteogenic materials, bone cement, and ceramics for bone void filling. The products include QuickSet, which is an injectable, self-hardening, macroporous, calcium-phosphate bone void filler cement covered by patent applications. It is used for bone reconstructive and trauma surgery, fracture repair, extremities or pelvis, complex fractures, joint arthroplasty, tibial osteotomy. It has received FDA clearance for three 510(k) applications with its calcium phosphate materials, which are also CE marked.
- Jul 2022Series C$2M
- Mar 2019Series C$4.7M
- Jan 2011Series C$5.3M
#9
Acquired · Valbonne, Provence Alpes Cote d Azur · founded 2001 · 45 employees$44.9Mraised▾
Developer of personalized immunotherapies for chronic inflammatory diseases. The proprietary platform uses the immuno-modulatory properties of peripheral blood antigen-specific Type 1 regulatory T cells (Ag-Treg). The lead candidate Ovasave has completed Phase II trials for refractory Crohn's disease. Another candidate for autoimmune uveitis.
- Feb 2017Post IPO$11.6M
- Jun 2016Post IPO$22.5M
- Aug 2015Grant (prize money)$1.5M
- Jul 2015Post IPO$8.7M
#10
Deadpooled · Valbonne, Provence Alpes Cote d Azur · founded 2020 · 27 employees$24.2Mraised▾
The developer of novel therapeutic solutions for the treatment of skeletal disorders. The company has developed a gene therapy for treating SEDc, severe skeletal, joint malformations, and abnormalities affecting the eyes and ears.
- Dec 2020Series A$24.2M
#11
Acqui-Hired · Marseille, Provence Alpes Cote d Azur · founded 2015 · 240 employees$31.3Mraised▾
Developer of diagnostic product for colon cancer. The company offers HalioDx assays to determine the degree of severity of the patient’s disease and to predict response to treatment, and the molecular class of its tumor. It develops a unique line of immunologic scoring tests used in oncology which include Immunoscore for colon cancer and non-small cell lung cancer.
- Jan 2019Grant (prize money)—
- Jan 2018Series B$22.7M
- Jan 2018Grant (prize money)$501.7K
- Mar 2015Series A$8.7M
#12
Public · Valbonne, Provence Alpes Cote d Azur · founded 2002 · 163 employees$5.3Mraised▾
Provider of medical imaging software and services for clinical trial usage. The company's SaaS-based Lesion Management Solutions (LMS) detect, evaluate, and follow up automatically and semi-automatically lesions identified in computed tomography (CT) scans. Serves two primary markets drug development and patient care. The product has the ability to detect cancer cells using computer-aided detection technology.
- Mar 2021Post IPO$33.2M
- Jul 2015Post IPO$22M
- Aug 2014Post IPO$26.4M
- Nov 2004Series A$5.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in France
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,220 France-affiliated papers.
- Centre National de la Recherche Scientifique280
- Inserm169
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement144
- Ministry of Agriculture118
- AgroParisTech36
- Gene3→26
- Genome2→14
- Antibody1→10
- Cell culture1→10
- Mutant1→10
- Gene2→30
- Agriculture1→20
- Selection (genetic algorithm)2→18
- Resistance (ecology)2→16
- Population1→12
- Agriculture2→13
- Antibiotic resistance3→12
- Population1→9
- Public health1→8
- Context (archaeology)2→9
Where biotechnology is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in France
France biotechnology patent filing is cooling — 34,222 filings from 8,000 assignees (2016–2025), led by Centre NAT RECH Scient, INST NAT Sante RECH MED, Sanofi; annual filings 3501→2745.
- Centre NAT RECH Scient10040
- INST NAT Sante RECH MED8292
- Sanofi3990
- Pasteur Institut3416
- Agronomique INST NAT RECH1331
- Cellectis1320
- PF Medicament1203
- Commissariat Energie Atomique1151
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.